多中心型Castleman病的治疗进展(7)

[18]Chronowski GM, Ha CS, Wilder RB, et al. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer 2001,92(3):670-6.

[19]Scott D, Cabral L, Harrington WJ Jr. Treatment of HIV-associated multicentric Castleman's disease with oral etoposide. Am J Hematol 2001, 66(2):148-50.

[20]Oksenhendler E, Duarte M, Soulier J, et al. Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients. AIDS 1996, 10(1):61-7.

[21]Repetto L, Jaiprakash MP, Selby PJ, et al. Aggressive angiofollicular lymph node hyperplasia (Castleman's disease) treated with high dose melphalan and autologous bone marrow transplantation. Hematol Oncol 1986, 4(3):213-7.

[22]Ide M, Kawachi Y, Izumi Y, et al. Long-term remission in HIV-negative patients with multicentric Castleman's disease using rituximab. Eur J Haematol 2006, 76(2):119-23.

[23]Ramasamy K, Gandhi S, Tenant-Flowers M, et al. Rituximab and thalidomide combination therapy for Castleman disease. Br J Haematol 2012,158(3):421-3.

[24]Casquero A, Barroso A, Fernández Guerrero ML, et al. Use of rituximab as a salvage therapy for HIV-associated multicentric Castleman disease. Ann Hematol 2006, 85(3):185-7.

[25]Puzik A,Thiel A,Faust K,H#228;rtel C.Thalidomide has anti-inflammatory properties in neonatal immune cells.Innate Immun.2013,19(1):42-52.

[26] Casper C, Teltsch DY, Robinson D Jr, et al. Clinical characteristics and healthcare utilization of patients with multicentric Castleman disease. Br J Haematol. 2015,168(1):82-93.

[27]Kedes DH, Ganem D. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest 1997, 99(9):2082-6.

[28]Casper C, Nichols WG, Huang ML, et al. Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood 2004,103(5):1632-4.

文章来源：《国际药学研究杂志》 网址: http://www.gjyxyjzz.cn/zonghexinwen/2020/1010/352.html